Independent Laboratory Verification: What HPLC and Mass Spectrometry Can—and Cannot—Prove

“Lab tested” is not a complete scientific claim. A credible analytical report must identify the sample, the method, the result, the laboratory and the limits of what was measured. Different tests answer different questions, and no single chromatogram or spectrum establishes every aspect of quality.

This guide explains how high-performance liquid chromatography (HPLC), mass spectrometry (MS) and related controls are used in peptide research—and where interpretation commonly goes wrong.

What “independent” should mean

An independent laboratory is organisationally separate from the party whose sample or claim is being evaluated. Independence is strengthened when the laboratory controls its own methods, calibrations, quality system and reporting; receives an identifiable sample under documented conditions; and reports results without the client editing the scientific conclusion.

Independence alone does not establish competence. The laboratory’s accreditation, the exact scope of that accreditation and the suitability of the method for the sample all matter.

Five separate quality questions

A strong report states which question each test addresses:

1. Identity: Is the target molecule present?
2. Purity: What proportion of detected material is attributed to the target under the stated method?
3. Quantity or assay: How much target material is present?
4. Microbiological quality: Does the sample meet a defined sterility or microbial-limit specification?
5. Endotoxin: Is bacterial endotoxin below a specified limit using an appropriate validated test?

Passing one does not imply passing the others. A result consistent with molecular mass does not establish sterility. A high chromatographic area percentage does not, by itself, prove the amount in a container.

What HPLC can show

HPLC separates components according to their interaction with a stationary phase and a moving solvent system. A detector records signals over time, producing a chromatogram. For peptides, reversed-phase HPLC with ultraviolet detection is commonly used to examine the main peak and related impurities.

A reported “purity percentage” is often an area normalisation: the area of the nominated peak divided by the total integrated peak area under specified conditions. That can be useful for comparing detectable components, but it is method-dependent.

Important HPLC limitations

• Some impurities may not absorb strongly at the selected wavelength.
• Two substances can co-elute and appear as one peak if separation is inadequate.
• Integration settings, baseline selection and excluded peaks can change the percentage.
• Area percentage is not automatically equivalent to mass fraction or content per vial.
• The diluent, column, gradient, temperature, flow rate and sample preparation influence the result.

A chromatogram is therefore meaningful only with enough method detail to understand selectivity, system suitability and integration.

What mass spectrometry can show

Mass spectrometry measures mass-to-charge ratios of ionised molecules. For peptide analysis, an observed intact mass consistent with the expected molecule can provide strong support for identity. Tandem mass spectrometry can add sequence-level evidence by examining fragmentation patterns.

Important MS limitations

• A matching mass is evidence for identity, not proof of overall purity.
• Different compounds or modified forms can sometimes have similar nominal masses.
• Ionisation efficiency varies, so signal intensity is not a simple measure of concentration.
• Salts, adducts, degradation products and multiply charged ions require expert interpretation.
• An MS spectrum does not establish sterility, endotoxin control or container contents.

Why combining methods is stronger

Orthogonal methods—techniques based on different physical principles—reduce the chance that one method’s blind spot controls the conclusion. HPLC can demonstrate separation and relative peak composition, while MS can support molecular identity. Quantitative assay may require a qualified reference standard and a separately validated procedure. Microbiological and endotoxin questions require their own methods.

Method validation: the missing context

A method should be fit for its intended purpose. The international ICH Q2(R2) guideline describes validation characteristics including specificity or selectivity, accuracy, precision, range, and—where appropriate—detection and quantitation limits. Robustness and system-suitability controls help show that routine operation remains reliable.

The required evidence depends on the method’s purpose. An identity procedure, an impurity test and a quantitative assay do not have identical validation requirements. A report that merely names “HPLC” without defining the analytical objective is incomplete.

Accreditation: check the exact scope

In Australia, the National Association of Testing Authorities (NATA) accredits organisations against relevant standards and publishes a searchable directory. Accreditation is not a universal badge covering every test a laboratory performs. The public scope should be checked for the specific field, method or class of testing relevant to the result.

A laboratory may be accredited for some activities and perform other work outside its accredited scope. Reports should make that distinction clear.

A certificate-of-analysis checklist

Before treating a certificate of analysis (CoA) as useful evidence, look for:

• laboratory name, address and report identifier;
• sample description, client or submitter reference and unique sample ID;
• date received, date tested and date reported;
• condition of the sample on receipt and any chain-of-custody information;
• method identifier and analytical objective;
• actual numerical results with units—not only “pass”;
• specification or acceptance criterion, if one was legitimately defined;
• measurement uncertainty where relevant;
• chromatogram, spectrum or supporting data linked to the same sample;
• authorised signatory and clear amendments/version history;
• statement of whether the test is within the laboratory’s accredited scope.

Common red flags

• A generic report with no lot, batch or sample identifier.
• A cropped chromatogram that omits axes, integration or run information.
• “99% pure” without a method, detector wavelength or calculation basis.
• An MS result presented as proof of sterility or potency.
• A report reused for multiple lots without a documented sampling rationale.
• An accreditation logo without a verifiable laboratory entry and relevant scope.
• Marketing language that goes beyond the laboratory’s stated conclusion.

Sampling is part of the evidence

Even a technically excellent analysis applies directly only to the sample received. It does not automatically represent every unit in a lot. Representative sampling, tamper-evident handling, documented custody and a defensible sampling plan determine how far a result can be generalised.

Source documents

• ICH Q2(R2): Validation of Analytical Procedures
• NATA: Find an accredited organisation
• Australian Government overview of NATA

Editorial note: This is general scientific information. It does not validate any particular product, batch, supplier or laboratory, and it is not medical or procurement advice.